IL33 and leukemia: Qin L et al showed that systemic administration of recombinant IL-33 dramatically inhibited the leukemia growth and prolonged the survival of leukemia-bearing mice by increasing the expansion and IFN-γ production of leukemia-reactive CD8 T cells [38].